

**We Claim:**

1. A pharmaceutical composition comprising a tailored  $\alpha_1$ -adrenoceptor antagonist, a bladder-selective antagonist and optionally included 5 $\alpha$ -reductase inhibitor, optionally together with pharmaceutically acceptable carriers, excipients or diluents.
2. The pharmaceutical composition according to claim 1 wherein the tailored  $\alpha_1$  AR antagonist is selective for  $\alpha_{1a}$  over  $\alpha_{1b}$  subtype but non-selective for  $\alpha_{1a}$  over  $\alpha_{1d}$  subtype.
3. The pharmaceutical composition according to claim 1 wherein the tailored  $\alpha_1$  AR antagonist is more than about 10 fold selective for  $\alpha_{1a}$  over  $\alpha_{1b}$  subtype and is less than about 10 fold selective for  $\alpha_{1a}$  over  $\alpha_{1d}$  subtype in receptor binding and *in vitro* functional assay.
4. The pharmaceutical composition according to claim 3 wherein the tailored  $\alpha_1$  adrenoceptor antagonist is selected from:  
1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,  
2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isindole-1,3(2H)-dione,  
5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,  
and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer, racemate, polymorphs, N- oxides or metabolites.
5. The pharmaceutical composition according to claim 3 wherein the tailored  $\alpha_1$  adrenoceptor antagonist is selected from:  
1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,  
2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isindole-1,3(2H)-dione hydrochloride salt and  
5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide hydrochloride salt.
6. The pharmaceutical composition according to claim 1, wherein the bladder selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

7. The pharmaceutical composition according to claim 6 wherein the bladder-selective antagonist is selected from:

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)phenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,

N-methyl-N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, N-oxide or metabolites.

8. The pharmaceutical composition according to claim 6 wherein the bladder-selective antagonist is selected from:

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate L-(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L-(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L-(+)-tartrate salt,

(2R)-(+)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartrate salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide tartrate salt,

(2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

N-{[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]}-2-cyclopentyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

(2R)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R, 2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

(2R, 2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide tartrate salt,

(2R, 2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(2R)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide tartrate salt,

2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate hydrochloride,

N-methyl-N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(2R) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide succinate salt,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate succinate salt,

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester and

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester with (2E)-2-butenedioate.

9. The pharmaceutical composition according to claim 1 wherein said 5 $\alpha$ -reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

10. The pharmaceutical composition according to claim 9 wherein the 5 $\alpha$ -reductase inhibitor is a dual type 1 and type 2 inhibitor.
11. The pharmaceutical composition according to claim 10 wherein the dual type 1 and type 2 inhibitor is dutasteride.
12. The pharmaceutical composition according to claim 9 wherein the 5 $\alpha$ -reductase inhibitor is a type 2 inhibitor.
13. The pharmaceutical composition according to claim 12 wherein the type 2 inhibitor is finasteride.
14. A pharmaceutical product or medicament comprising a first pharmaceutical composition of a tailored  $\alpha_1$  adrenoceptor antagonist, a second pharmaceutical composition of a bladder selective antagonist and optionally included a third pharmaceutical composition of 5 $\alpha$ -reductase inhibitor.
15. A pharmaceutical product or medicament of claim 14 wherein the product or medicament is a combined preparation.
16. A pharmaceutical product or medicament according to claim 15 wherein the combined preparation is single dosage form.
17. A pharmaceutical product or medicament according to claim 15 wherein the combined preparation comprises separate dosage forms.
18. A pharmaceutical product or medicament according to claim 14 wherein the tailored  $\alpha_1$  AR antagonist is selective for  $\alpha_{1a}$  over  $\alpha_{1b}$  subtype but non-selective for  $\alpha_{1a}$  over  $\alpha_{1d}$  subtype.
19. A pharmaceutical product or medicament according to claim 14 wherein the tailored  $\alpha_1$  AR antagonist is more than about 10 fold selective for  $\alpha_{1a}$  as compared to  $\alpha_{1b}$  subtype and is less than about 10 fold selective for  $\alpha_{1a}$  over  $\alpha_{1d}$  subtype in receptor binding and *in vitro* functional assay.
20. The pharmaceutical product or medicament according to claim 19 wherein the tailored  $\alpha_1$  adrenoceptor antagonist is selected from:

1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,  
 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione,  
 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,  
 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer, racemate, polymorphs, N- oxides or metabolites.

21. The pharmaceutical product or medicament according to claim 19 wherein the tailored  $\alpha_1$  adrenoceptor antagonist is selected from:

1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,  
 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride salt and  
 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide hydrochloride salt.

22. A pharmaceutical product or medicament according to claim 14 wherein the bladder-selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

23. A pharmaceutical product or medicament according to claim 22 wherein the bladder-selective antagonist is selected from:

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,  
 (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,  
 (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,  
 (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,  
 (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]-hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,

N-methyl-N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, N-oxide or metabolites.

24. A pharmaceutical product or medicament according to claim 22 the wherein bladder-selective antagonist is selected from:

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate L-(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt,

(2R)-(+)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartrate salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)phenyl acetamide tartrate salt,

(2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

N-{[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]}-2-cyclopentyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

(2R)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R, 2S)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

(2R, 2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide tartrate salt,

(2R, 2S)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(2R)-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide tartrate salt,



2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate hydrochloride,

N-methyl-N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(2R) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide succinate salt,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate succinate salt,

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester and

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester with (2E)-2-butenedioate.

25. A pharmaceutical product or medicament according to claim 14 wherein the 5 $\alpha$ -reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

26. A pharmaceutical product or medicament according to claim 25 wherein the 5 $\alpha$ -reductase inhibitor is a dual type 1 and type 2 inhibitor.

27. A pharmaceutical product or medicament according to claim 26 wherein the dual type 1 and type 2 inhibitor is dutasteride.

28. A pharmaceutical product or medicament according to claim 25 wherein the 5 $\alpha$ -reductase inhibitor is a type 2 inhibitor.

29. A product or medicament according to claim 28 wherein the type 2 inhibitor is finasteride.

30. A method for treatment of a mammal suffering from lower urinary tract symptoms (LUTS) associated with or without BPH, comprising administering to said mammal, a therapeutically effective amount of a product or medicament, comprising a

tailored  $\alpha_1$  AR antagonist, a bladder-selective antagonist and optionally included  $5\alpha$ -reductase inhibitor.

31. The method according to claim 30 wherein mammal is animal.
32. The method according to claim 30 wherein mammal is human.
33. The method according to claim 32 wherein human is man.
34. The method according to claim 32 wherein human is woman.
35. The method according to claim 30 wherein the said product or medicament is administered as a combined preparation.
36. The method according to claim 35 wherein the combined preparation is administered as single dosage form.
37. The method according to claim 35 wherein the combined preparation is administered in separate dosage forms.
38. The method according to claim 37 wherein the separate dosage forms are administered simultaneously.
39. The method according to claim 37 wherein the separate dosage forms are administered separately.
40. The method according to claim 37 wherein the separate dosage forms are administered sequentially.
41. The method according to claim 30 wherein the tailored  $\alpha_1$  AR antagonist is selective for  $\alpha_{1a}$  over  $\alpha_{1b}$  subtype but non-selective for  $\alpha_{1a}$  over  $\alpha_{1d}$  subtype AR antagonist.
42. The method according to claim 30 wherein the tailored  $\alpha_1$  AR antagonist is more than about 10 fold selective for  $\alpha_{1a}$  as compared to  $\alpha_{1b}$  subtype and is less than about 10 fold selective for  $\alpha_{1a}$  as compared to  $\alpha_{1d}$  subtype in receptor binding and functional assay.
43. The method according to claim 42 wherein the tailored  $\alpha_1$  AR antagonist is selected from:  
1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,

2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione,

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,

and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer, racemate, polymorphs, N-oxides or metabolites.

44. The method according to claim 42 wherein the tailored  $\alpha_1$  AR antagonist is selected from:

1-{3-[4-(2-methoxyphenyl)piperazin-1-yl]-propyl}-piperidine-2,6-dione hydrochloride salt,

2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride salt and

5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide hydrochloride salt.

45. The method according to claim 30 wherein the bladder-selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

46. The method according to claim 45 wherein the bladder-selective antagonist is selected from:

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)phenyl acetamide,

N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide,

N- {[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]}-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,

N-methyl-N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, N-oxides or metabolites.

47. The method according to claim 45 wherein the bladder-selective antagonist is selected from:

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate L(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)-tartrate salt,

(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt,

(2R)-(+)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

- (2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,
- (2S)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,
- (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartrate salt,
- (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,
- N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)phenyl acetamide tartrate salt,
- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,
- N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,
- (2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,
- (2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,
- (2R, 2S)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,
- (2R, 2S)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide tartrate salt,
- (2R, 2S)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,
- (2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,
- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide tartrate salt,
- 2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate hydrochloride,
- N-methyl-N-(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,
- (2R) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,
- (2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide succinate salt,

(2R)- (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate,

(1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate succinate salt,

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester and

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester with (2E)-2-butenedioate.

48. The method according to claim 30 wherein the 5 $\alpha$ -reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual type 1 and type 2 inhibitor.

49. The method according to claim 48 wherein the 5 $\alpha$ -reductase inhibitor is a dual type 1 and type 2 inhibitor.

50. The method according to claim 49 wherein the dual type 1 and type 2 inhibitor is dutasteride.

51. The method according to claim 48 wherein the 5 $\alpha$ -reductase inhibitor is a type 2 inhibitor.

52. The method according to claim 51 wherein the type 2 inhibitor is finasteride.